Eaton Corp PLC

1. 1

   Electing the 11 Director Nominees

   ManagementBoard: FOR

   Election of eleven nominated directors to the Board for one-year terms ending at the 2027 annual general meeting.

2. 2

   Approving the Appointment of the Independent Auditor for 2026 and Authorizing the Audit Committee to Set Auditor Remuneration

   ManagementBoard: FOR

   Reappoint Ernst & Young LLP as independent auditor for fiscal year 2026 and authorize the Audit Committee to set the auditor's remuneration.

   More detail

   Shareholders are asked to reappoint Ernst & Young LLP as Eaton's independent auditor for the 2026 fiscal year and to authorize the Audit Committee to set the auditor’s remuneration. Management and the Audit Committee recommend reappointment based on Ernst & Young’s long tenure (auditor since 1923), deep knowledge of Eaton’s operations and industries, and perceived benefits for continuity and audit quality. The proposal is routine and standard: reappointing the incumbent auditor preserves audit continuity and leverages institutional knowledge about the company’s financial reporting and internal controls. The Audit Committee emphasizes that it has sole authority to appoint and compensate the auditor, reviews auditor independence and pre-approves non-audit services, and has concluded the scope and fees are appropriate. A representative of Ernst & Young will attend the meeting and be available to respond to shareholder questions. The Board’s recommendation points to audit firm expertise and longstanding relationship as the primary rationale; potential governance considerations for investors include auditor tenure, periodic firm rotation considerations, and the Audit Committee’s oversight of independence and non-audit services.

3. 3

   Approving, on an Advisory Basis, the Company's Executive Compensation

   ManagementBoard: FOR

   Non-binding advisory vote to approve the executive compensation disclosed in the Proxy Statement (Say-on-Pay).

   More detail

   This management proposal requests an advisory 'say-on-pay' approval of the Company's executive compensation as disclosed in the Proxy Statement, including the Compensation Discussion and Analysis and compensation tables. Although non-binding, the board and Compensation and Organization Committee view the vote as important feedback and will consider the results in future compensation decisions — the company previously received 93.2% support in 2025. The compensation program emphasizes pay-for-performance with approximately 80% of NEO pay at-target being performance-based, uses Adjusted EPS and Adjusted OCF for short-term incentives, and a TSR-based ESIP for long-term incentives. Management’s justification focuses on alignment with shareholder value, rigorous metrics, clawback policy, share ownership requirements, and other governance practices. Investors should weigh the strong historical shareholder support alongside the program’s design (relative TSR PSUs, time-based RSUs and options, caps, and clawback) and consider how well realized pay tracked multi-year performance, material governance features, and any potential pay-related risks.

4. 4

   Approving the Board of Directors' Authority to Issue Shares under Irish Law

   ManagementBoard: FOR

   Authorize the Board to allot relevant securities up to approximately 20% of issued ordinary share capital for 18 months under Irish law.

   More detail

   Proposal 4 seeks shareholder approval under Irish law to grant the Board authority to issue up to an aggregate nominal amount equal to approximately 20% of the company's issued share capital for an 18-month period. Management frames this as routine and customary for Irish-listed companies and not as an increase in authorized share capital, but as enabling the Board to act flexibly to issue already-authorized shares for general corporate purposes including acquisitions and capital raising. The request reflects standard market practice; investors should consider potential dilutive impact, the contemporaneous share repurchase program which can offset dilution, and safeguards such as the finite 18-month term and the Board’s fiduciary duty. The Board recommends approval because it provides necessary flexibility in capital management while remaining within market norms.

5. 5

   Approving the Board of Directors' Authority to Opt-Out of Pre-emption Rights under Irish law

   ManagementBoard: FOR

   Special resolution to empower the Board to allot equity securities for cash without first offering them pro-rata to existing shareholders, limited to certain rights issues and up to ~20% issuance for 18 months, conditional on Proposal 4.

   More detail

   Proposal 5 requests a special resolution to permit the Board, subject to passing Proposal 4, to disapply statutory pre-emption rights—i.e., to allot equity securities for cash without a pro-rata offer to existing shareholders—in specified circumstances limited to rights issues and otherwise up to approximately 20% of issued share capital for 18 months. Management argues this is customary in Ireland and necessary to permit efficient capital raising and strategic transactions without procedural delay. Investors should weigh the standard market rationale against dilution risk; the proposal includes constraints (20% cap, 18-month term, and requirement of a 75% shareholder approval) that mitigate abuse while aligning Eaton with common practices for NYSE-listed Irish companies.

6. 6

   Authorizing the Company and Any Subsidiary of the Company to Make Overseas Market Purchases of Company Shares

   ManagementBoard: FOR

   Authorize the Company and any subsidiary to repurchase up to ~10% of shares (38,791,602 shares) in the open market over 18 months, with price limits between 70% and 120% of prior NYSE closing price.

   More detail

   This proposal requests an ordinary resolution authorizing the Company and its subsidiaries to repurchase up to approximately 10% of the Company’s outstanding shares in the open market over an 18-month period with specified price collars (70%–120% of prior day’s NYSE closing price). Management frames this as a standard capital allocation tool to return value to shareholders and manage dilution, noting historical repurchases and that the authority would allow subsidiaries to participate in repurchases under Irish law. Investors evaluating the proposal should consider the potential for efficient capital deployment and EPS accretion versus alternative uses of capital, and the existence of guardrails (share cap, price limits, and time limit) which reduce the risk of opportunistic repurchases.

Upcoming shareholder meetings at Eaton Corp PLC’s closest sector peers — compare boards, ballots, and ownership across the cohort.

When is the Eaton Corp PLC 2026 annual meeting?

Eaton Corp PLC (ETN) holds its 2026 annual shareholder meeting on Wednesday, April 22, 2026.

What is the record date for the Eaton Corp PLC 2026 meeting?

The record date for the Eaton Corp PLC 2026 meeting is Monday, February 23, 2026. Shareholders of record on or before that date are eligible to vote.

Who are the director nominees for Eaton Corp PLC's 2026 meeting?

The board is presenting 11 director nominees at the Eaton Corp PLC 2026 meeting, listed with their independence status and background.

What proposals will shareholders vote on at the Eaton Corp PLC 2026 meeting?

Shareholders will vote on 6 proposals at the Eaton Corp PLC 2026 meeting, each tagged with who proposed it and the board's recommendation.